Owners, management and financials
CVR: 38768964
DKK 4,455,235
Gross profit
Net result: DKK 1,662,593
CMA HOLDING RANDERS ApS (100%)
CVR · view owners
Peter Møller Lassen
Board: Michael Maigaard Nielsen (chair) and 2 members
CVR · view management
Active
Founded 23 June 2017
CVR · view overview
2 employees
CVR · 2026
Director registered: Peter Møller Lassen
CVR · 17/10/2017
View the full event history
Innosurge Biologics A/S is a Danish company of the type Aktieselskab based in Randers NV, founded in 2017. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The management consists of Peter Møller Lassen. The board consists of Michael Maigaard Nielsen (chair), Heinz Kvottrup Lorentzen and Peter Møller Lassen. The company is owned by CMA HOLDING RANDERS ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 4,455,235 and a net result of DKK 1,662,593 compared with DKK 251,617 the year before. Equity in the 2025 report amounted to DKK 2,897,096.
Source: annual report 2025, Danish Business Authority
Innosurge Biologics A/S has shown a positive trajectory in profitability, with gross profit increasing from 992,732 DKK in 2021 to 4,455,235 DKK in 2025, and profits rising significantly from a loss of 613,437 DKK in 2021 to a profit of 1,662,593 DKK in 2025. The company's equity has also improved, reaching 2,897,096 DKK in 2025, indicating a strengthening financial position. However, the absence of revenue figures raises concerns about transparency and overall sales performance. Positioned within the medical and hospital supplies wholesale industry, Innosurge appears to be gaining traction, but its reliance on gross profit rather than disclosed revenue may warrant further scrutiny.
AI-generated summary · Generated 14/08/2026
Selskabets formål er at drive virksomhed med engroshandel med læge- og hospitalsartikler og hermed forbundet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 4.5 mio. | 1.7 mio. | 5.7 mio. | 2.9 mio. | 2 | |
| 202401/01/2024 – 31/12/2024 | 2.4 mio. | 252 t. | 3.6 mio. | 2 mio. | 2 | |
| 202301/01/2023 – 31/12/2023 | 2.1 mio. | 407 t. | 4.7 mio. | 1.7 mio. | 2 | |
| 202201/01/2022 – 31/12/2022 | 2.2 mio. | 490 t. | 4.6 mio. | 1.3 mio. | 3 | |
| 202101/01/2021 – 31/12/2021 | 993 t. | -613 t. | 3.8 mio. | 836 t. | 3 | |
| 202001/01/2020 – 31/12/2020 | -695 t. | -2.6 mio. | 3.1 mio. | 1.4 mio. | 3 | |
| 201901/01/2019 – 31/12/2019 | 1.2 mio. | 290 t. | 4.3 mio. | 2 mio. | 2 | |
| 201801/01/2018 – 31/12/2018 | 1.7 mio. | 799 t. | 5 mio. | 1.8 mio. | 1 |
Compared to 292 companies in Engroshandel med læge- og hospitalsartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Innosurge Biologics A/S is 38768964.
Innosurge Biologics A/S is owned by CMA HOLDING RANDERS ApS.
The management of Innosurge Biologics A/S consists of Peter Møller Lassen.
The board of Innosurge Biologics A/S consists of Michael Maigaard Nielsen, Heinz Kvottrup Lorentzen and Peter Møller Lassen, with Michael Maigaard Nielsen as chair.
In 2025, Innosurge Biologics A/S reported a gross profit of DKK 4,455,235.
Innosurge Biologics A/S had 2 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Innosurge Biologics A/S has published its annual report for 2025. Gross profit came to DKK 4,455,235, and the net result was DKK 1,662,593.
Innosurge Biologics A/S has published its annual report for 2024. Gross profit came to DKK 2,444,975, and the net result was DKK 251,617.
Innosurge Biologics A/S has published its annual report for 2023. Gross profit came to DKK 2,077,814, and the net result was DKK 406,817.
As of October 1, 2023, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of Innosurge Biologics A/S.
As of October 1, 2023, Kvist & Jensen Statsautoriseret Revisionspartnerselskab has stepped down as auditor of Innosurge Biologics A/S.
Innosurge Biologics A/S has published its annual report for 2022. Gross profit came to DKK 2,183,245, and the net result was DKK 489,687.
Innosurge Biologics A/S has published its annual report for 2021. Gross profit came to DKK 992,732, and the net result was DKK -613,437.
Innosurge Biologics A/S has published its annual report for 2020. Gross profit came to DKK -695,490, and the net result was DKK -2,600,178.
Innosurge Biologics A/S has published its annual report for 2019. Gross profit came to DKK 1,241,663, and the net result was DKK 290,106.
As of April 20, 2020, Heinz Kvottrup Lorentzen has joined the board of directors of Innosurge Biologics A/S.
As of April 20, 2020, Svend Aage Jensen has left the board of directors of Innosurge Biologics A/S.
As of April 19, 2020, Heinz Kvottrup Lorentzen has left the board of directors of Innosurge Biologics A/S.
Innosurge Biologics A/S has published its annual report for 2018. Gross profit came to DKK 1,740,667, and the net result was DKK 799,342.
Innosurge Biologics A/S has published its interim report for the period June 23, 2017 to December 31, 2017.
As of October 17, 2017, Svend Aage Jensen has joined the board of directors of Innosurge Biologics A/S.
As of October 17, 2017, Heinz Kvottrup Lorentzen has joined the board of directors of Innosurge Biologics A/S.
As of October 17, 2017, Peter Møller Lassen is registered as adm. dir. of Innosurge Biologics A/S.
As of October 16, 2017, Heinz Kvottrup Lorentzen has left the board of directors of Innosurge Biologics A/S.
As of October 16, 2017, Peter Møller Lassen has stepped down as director of Innosurge Biologics A/S.
As of June 23, 2017, Kvist & Jensen Statsautoriseret Revisionspartnerselskab has been appointed auditor of Innosurge Biologics A/S.
As of June 23, 2017, Heinz Kvottrup Lorentzen has joined the board of directors of Innosurge Biologics A/S.
As of June 23, 2017, Michael Maigaard Nielsen has joined the board of directors of Innosurge Biologics A/S.
As of June 23, 2017, Peter Møller Lassen has joined the board of directors of Innosurge Biologics A/S.
As of June 23, 2017, Peter Møller Lassen is registered as director of Innosurge Biologics A/S.
As of June 23, 2017, CMA HOLDING RANDERS ApS is registered as an owner of Innosurge Biologics A/S with an ownership share of 100%.
Innosurge Biologics A/S was founded on June 23, 2017.
Companies in the same industry and area
CVR 31492572
CVR 38891308
CVR 44334178
CVR 14653538
CVR 40862676
